Back

Biochemical and Immunological Properties of Engineered Low-Immunogenic Staphylokinases for Next-Generation Thrombolytic Therapy

Strunga, A.; Peskova, M.; Krupka, M.; Zachova, K.; Sindlerova, L.; Neumeisterova, N.; Mican, J.; Vitecek, J.; Bednar, D.; Kubala, L.; Raska, M.; Damborsky, J.; Prokop, Z.

2026-01-04 biochemistry
10.64898/2026.01.04.697554 bioRxiv
Show abstract

Staphylokinase (SAK) is a highly fibrin-specific plasminogen activator with significant potential as a safe and affordable thrombolytic. Yet, its clinical translation can be limited by potential immunogenicity. To accelerate the development of improved thrombolytics, a critical step is identifying the most suitable molecular template. Therefore, we performed a comparative analysis of biochemical and immunological properties of three engineered low-immunogenic variants (SAK SY155, SAK THR174, and SAK STAR FRIDA) and two wild-types (SAK STAR and SAK 42D), using a newly established panel of assays. All variants retained potent thrombolytic activity, with SAK SY155 displaying the highest catalytic efficiency and fibrin-clot permeability. However, this advantage did not fully translate into improved clot reduction under flow conditions. Comprehensive immunological profiling, including monocyte activation, T lymphocyte proliferation, dendritic cell maturation, and mouse immunization models, revealed no strong immunogenic response in any tested variant. Overall, low-immunogenic SAK SY155 and its background wild-type SAK STAR emerged as the most promising templates for rational engineering of next-generation thrombolytics.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.